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Abstract
Pain is a physiologic mechanism of the human body. Early cultures believed pain 
to have demonic and spiritual origins. In the early nineteenth century, morphine 
was first isolated by the German pharmacist Friedrich Wilhelm Adam Ferdinand 
Serturner. Since then, synthetic opioids and other derivatives of morphine have 
been developed for a wide variety of purposes, including pain relief during surgery. 
Opioids mainly act through the stimulation of μ-receptors, which has inhibitory 
effects on the propagation of pain signals to the brain. However, opioids also have 
unwanted side effects like nausea, vomiting, constipation, postoperative sedation, 
dizziness, and addiction, and are associated with significant morbidity, prolong 
hospital stays, increase use of medications needed to reverse side effects, and 
decrease patient satisfaction. Furthermore, use and abuse of opioids have contributed 
to an opioid epidemic, especially in the United States since the beginning of the 
twenty-first century. Opioid-free anesthesia is an alternative aimed at providing pain 
relief without the opioid-related adverse effects and to enhance recovery. Non-opioid 
alternatives and preoperative patient education strategies have been shown to be 
superior in the management of postoperative pain and opioid requirements. Clinicals 
have embraced these concepts enthusiastically and have begun to incorporate an 
opioid-free pain management approach in surgery.
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1. Introduction
The perception of pain is an integral part of human existence. Although uncomfort-
able to the individual, the perception of pain is necessary to protect the body from harm. 
A painful sensation causes man to seek an explanation for the reason of this discomfort. 
A brief history of the origins of pain and the development of pain medications is 
presented, followed by the current understanding of the physiology of pain and modern 
concern about opioid use. In the second half of the twentieth century, synthetic opioids 
were introduced to achieve hemodynamic stability during anesthesia. Furthermore, 
combined with hypnotics and muscle relaxants, the opioids administration is consid-
ered a keystone of anesthesia. For instance, a prevalence of 30% of unwanted effects of 
opioids such as nausea, vomiting, dizziness and constipation has been reported [1].  
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An increased occurrence of confusion and postoperative delirium [2], respiratory 
depression, increased postoperative pain and opioids consumption with abuse, immu-
nodepression, hyperalgesia and chronic postoperative pain have also been described. Of 
note, opioid tolerance to analgesia can occur after a single dose. Thus, the management 
of pain in surgery is currently moving in the direction of the reduction of opioid use 
preoperatively, perioperatively, and postoperatively. The modern multimodal anesthesia 
and analgesia with intraoperative hemodynamic stability, immobility and anticipation 
of postoperative analgesia can be achieved without opioids. The concept of opioid-free 
anesthesia (OFA) is based on the idea that hemodynamic stability can be obtained with-
out opioids during anesthesia. In particular, OFA is a fascinating multimodal approach 
to anesthesia which provides the combination of hypnotics, N-methyl-D-aspartate 
(NMDA) antagonists, local anesthetics, anti-inflammatory drugs and alpha-2 agonists 
such as dexmedetomidine, and no intra-operative systemic, neuraxial, or intracavitary 
opioid is administered during anesthesia and the perioperative course. This strategy is 
aimed to prevent postoperative opioid-related adverse effects and to enhance recovery 
after surgery.
2.  Pain and pain management from ancient cultures to the nineteenth 
century
Early theories of the origin of pain, especially from internal diseases, revolved 
around demonic and religious beliefs. Shamans and sorcerers treated patients with 
the use of amulets, magic sculptures, talismans, magic ceremonies and rituals to 
ward off demons and evil spirits. It was believed that spirits and demons should 
leave the body from the same way it entered, resulting in cultural scarifications to 
allow bad fluids, spirits and demons to escape. In Egypt, religious ceremonies and 
prayers were believed to help relieve pain. Incantations to God Horus and other 
deities were thought to relieve unilateral headaches [3].
Ancient cultures have used leaves of cocoa plant and opium for religious and 
medical purposes. The earliest anthropological evidence of the use of cocoa leaves 
was from the pre-Inca culture in Peru, dated to 1300 B.C. The Peruvians used cocoa 
leaves as a local anesthetic in trepanation operations. Opium was introduced to 
Egypt around 1500–1300 B.C., and was used as a cream for external application and 
for the fumigation of toothaches. In India and China, opium was used for the treat-
ment of toothache and joint pain. In these cultures, opium could not be separated 
from its “recreational” use [3].
In the seventeenth century, physicians began to consider the human body as 
a machine with different parts in constant motion. The French philosopher Rene 
Descartes proposed one of the earliest concepts of modern physiology: a movement or 
touch initiated at the peripheral nerve endings propagated to the brain. This concept, 
which formed the basis of nineteenth century pain theories, is illustrated by Descartes 
famous figure [3] of a boy, whose foot is being stimulated by heat from a fire. Several 
scientific discoveries followed Descartes physiologic concept of pain, including that 
of Sir Humphrey Davy’s reports of pain relief from inhalation of nitrous oxide in 1800 
and James Moore’s report of opium use for postoperative analgesia in 1784 [3].
3. The era of opioid analgesics and the discovery of anesthesia
With a better understanding of the physiology and pathways of pain, pharma-
cologic discoveries, particularly of morphine, were made in the beginning of the 
nineteenth century. The German pharmacist Friedrich Wilhelm Adam Ferdinand 
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Serturner was the first to isolate morphine from poppy in 1805. He named the 
substance after Morpheus, the Greek god of sleep. The invention of the hypodermic 
hollow needles and syringes by Charles Gabriel Pravaz and Alexander Wood in the 
1850s allowed the ease of subcutaneous application. While this helped the wide-
spread use of morphine, it also paved way for the use and abuse of morphine that 
spread rapidly during the American Civil War (1861–1865) and the French-German 
War (1870–1871). Opioid addiction became known as the “soldier’s disease” and 
spurred research efforts to find substances with a lower risk of abuse [3].
Stemming from the discovery of morphine, scientists began to experiment and 
develop different forms of morphine. In 1874 Charles Adler Wright synthesized 
diacetyl-morphine, which in 1898 was registered under the name of heroin. This 
drug showed stronger cough suppression but lower analgesic effects when compared 
to morphine in animal models. Toward the beginning of the twentieth century, 
addiction to heroin became a growing problem in the USA, and in 1914, the govern-
ment began implementing stricter regulations, limiting the maximum amount of 
heroin in preparations. These regulations also prohibited opium, morphine, cocaine, 
and several other substances from non-prescription preparations [3].
The development of new opioid analgesics continued. Derivatives of morphine 
and codeine such as hydromorphone, dihydrocodeine, hydrocodone, oxymorphone, 
meperidine, and oxycodone emerged at the beginning of the twentieth century. 
Methadone was developed during World War II in Germany and was used primar-
ily as a substitution therapy in drug addicts. Methadone is a μ-receptor agonist 
and a noncompetitive NMDA antagonist. The NMDA receptor is involved in the 
pathophysiology of neuropathic pain. Fentanyl was developed by Paul A.J. Janssen 
in 1953 and was proved to be approximately 40 times more active than morphine. 
Subsequently, similar compounds with stronger potency developed, including 
carfentanil, sufentanil, and alfentanil [3].
The techniques for pain relief, such as spinal cord analgesia, knee surgeries, and 
different routes of administration for medications, began to develop after further 
research suggested opioid receptors in the human brain and the demonstration 
of endogenous opioids, the endorphins and enkephalins, constituting an internal 
system of pain modulation. Opioid receptors were found in high density in the sub-
stantia gelatinosa of the spinal cord, as well as the limbic system and periaqueductal 
gray area of the brainstem. This led to the reintroduction of spinal opioid applica-
tion in clinical medicine. Peripheral opioid receptors were demonstrated in the late 
1980s, and Stein and colleagues showed reduced operative pain following arthros-
copy of the knee joint following intraarticular injection of morphine. Sustained 
release formula and transdermal route of administration provided a profound 
impact on the management of chronic pain. It made pain management much more 
comfortable for the patients, resulting in an improved quality of life. Morphine was 
available in the sustained release formula in 1983, while fentanyl was available in the 
transdermal system. Various opioids in sustained release formula and transdermal 
systems followed [3].
Surgical anesthesia experimentations in the nineteenth century allowed for 
major development in pain-free surgeries. One of particular note was the Dr. 
William Morton’s experimentation with ether as a local anesthetic for a surgical 
neck operation. The dentist Horace Wells previously used gas during teeth extrac-
tion procedures. The first surgical ether anesthetized procedure was by the dentist 
William Thomas Green Morton at Massachusetts General Hospital, Boston, in 1846. 
Dr. John C. Warren was the senior surgeon operating on a congenital vascular tumor 
on the neck of a young man, Gilbert Abbott. To the audience’s amazement, Abbott 
did not cry out in pain during the procedure, and this ushered in the era of pain-
free surgery [3]. Painters Warren and Lucia Prosperi were commissioned in 2000 
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to immortalize this milestone in anesthetic surgery with a painting that became 
known as the Ether Dome painting.
Further significant steps in anesthesia in surgical environments continued. The 
use of chloroform in the management of childbirth was introduced into the medical 
world by Sir James Young Simpson in 1847, the same year physiologist Marie Jean 
Pierre Flourens had discovered the anesthetic properties of chloroform in animals. 
Chloroform remained the preferred anesthetic until the end of the nineteenth 
century even though the use of chloroform resulted in significantly more deaths 
than with ether [3].
Cocaine in local anesthesia marked another milestone in the advancement of 
pain management in surgery. During the nineteenth century, Albert Niemann, a 
scientist from Gottingen, isolated cocaine out of the mixture of alkaloids of the 
cocoa plant. The extracts became popular for conditions such as toothaches, diges-
tive disorders, hysteria, and melancholia, as well as for being an aphrodisiac. Carl 
Koller experimented with cocaine as a local anesthetic on frog eyes, other animals, 
his assistants, and even himself. His paper, which demonstrated cocaine’s efficacy, 
was presented at the Heidelberg Ophthalmological Society in 1884 by his colleague 
Josef Brettauer. The presentation was widely received and others began experiment-
ing with cocaine’s surgical applications [3].
After the Heidelberg presentation, scientists began experimenting with cocaine 
as a nerve block, in advanced cancer patients, and in spinal cord operations. 
American surgeon William Steward Halsted [4] began experimenting with cocaine 
as a nerve block, which opened up new possibilities in surgery anesthetics. Halsted 
and several of his colleagues eventually became addicted to cocaine during their 
experimentations with the drug. James Leonard Corning used cocaine as a spinal 
anesthetic in 1885. Dr. Herbert Snow was the first physician to incorporate cocaine 
into cancer pain treatment. In 1896, he administered cocaine with opium for 
pain relief to patients with advanced diseases. He later developed the “Brompton 
Cocktail,” a mixture containing morphine, cocaine, and alcohol. German surgeon 
August Bier and his colleagues published their clinical results of spinal anesthesia, 
including intrathecal injections on each other. He introduced intravenous regional 
anesthesia in 1908. Rudolph Matas administered the first morphine anesthetic to 
the spinal cord in 1909. Most of the nerve blocking techniques during this time 
period were developed for surgical anesthesia [3].
Further experimentation with cocaine as an analgesic continued during the 
nineteenth century, resulting in the development of new local anesthetics including 
synthetic substitutes. Alfred Einhorn synthesized procaine in 1905. Lofgren and 
Lundqvist synthesized Lignocaine in 1943. Other local anesthetics followed includ-
ing cinchocaine and amethocaine in the 1920s, mepivacaine, prilocaine, and bupiva-
caine in the late 1950s, etidocaine in the 1970s, and ropivacaine in the 1980s [3].
The current understanding of the physiology of pain involves the activation of 
the nervous system. Noxious stimuli, including intense thermal, mechanical, or 
chemical stimuli, are recognized by nociceptors in the peripheral nervous system. 
The threshold for pain activation is relatively high, requiring a large stimulus 
for signal propagation. The signals either travel through Aδ-fibers, Aβ-fibers, or 
C-fibers. While the Aδ-fibers and Aβ-fibers are myelinated and transmit “acute, 
well-localized, fast pain,” the C-fibers are unmyelinated and transmit “slow” 
pain, often described as an ache. The signals travel to the dorsal root ganglion, are 
transmitted through the spinal cord and synapse on the somatosensory cortex and 
limbic system. The modification of this pathway by medications aims to reduce or 
eliminate pain [5].
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4. The public health issue of prescription opioid abuse
Although opioids have historically been significant medications in the manage-
ment of pain, opioids have also been the source of significant public health concern 
because of the addictive and destructive adverse effects of the medication. During 
the twentieth century, there were positive attitudes for the use of opioids, as a letter 
written to the New England Journal of Medicine underscored the safety and low 
addictive potential of opioid use in chronic pain patients, with subsequent letters 
and reviews supporting this perspective. With the impression that there was very 
little risk, particularly of addictive potential, in prescribing opioids for chronic pain, 
the demand for opioid use increased in clinical settings. However, by 2000, attitudes 
are beginning to shift and a reduction of opioid use is becoming the trend [5].
The detrimental overuse, abuse and addiction of opioids can precipitate from 
prolonged treatment of opioids. Opioid tolerance occurs when there is a reduction 
in the analgesic and sedative effects of these medications. Tolerance to the euphoric 
effects also develop, further increasing the risk of addiction. Opioid dependence 
results from the overactivation of the somatomotor cortex and autonomic nervous 
system due to the increased signaling of the cells while on the inhibitory medica-
tions. Cessation of opioid use or the administration of opioid receptor antagonists 
such as naloxone or naltrexone cause the withdrawal symptoms, including diarrhea, 
vomiting, agitation, hyperalgesia, hyperthermia, and hypertension [5].
In the United States, the opioid abuse has reached epidemic proportions and 
have become a public health issue. The treatment of opioid dependence is unclear, 
but there have been significant public health prevention efforts to combat the trends 
of increased abuse and overdose deaths [5]. On the topic of opioid epidemic, the 
United States Surgeon General Dr. Jerome Adams supports overdose education and 
awareness, and suggests co-prescribing naloxone to patients on high morphine 
milligram equivalent who are at risk [6]. Nearly all the U.S. states have laws support-
ing naloxone provision to lay persons. Further, the U.S. Department of Health and 
Human Services highlighted naloxone rescue kit access and emergency overdose as 
a priority to address the opioid crisis. The benefits of naloxone programming have 
been demonstrated in San Francisco, as well as in North Carolina, where a 70% 
decline in prescription opioid-related overdose death rates was observed from 2009 
to 2010 [7].
5. Special issues on perioperative opioids administration
The current trend in surgery is in the direction away from general anesthesia 
that traditionally requires opioids preoperatively, intraoperatively, and postop-
eratively, and toward a more multi-modal regimen approach with preoperatively 
patient education, specifically highlighting the interplay between opioids and the 
human body’s natural pain management system.
Currently, many surgical operations have been traditionally performed under 
general anesthesia with adjunct opioid use. The main mechanism of action of opioids 
is the stimulation of μ receptors, which has inhibitory effects on the propagation of 
pain signals to the brain [8]. However, there are a wide variety of associated adverse 
effects of opioids including nausea, vomiting, constipation, postoperative sedation, 
dizziness, and addiction [9]. Opioid use also carries significant morbidity, prolong 
hospital stays, increase use of medications needed to reverse side effects, and decrease 
patient satisfaction [10, 11]. Further, opioids may also cause paradoxical hyperalgesia 
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due to opioid-induced neural plasticity. This appears to affect both the central and 
peripheral nervous systems, and may lead to sensitization of the pain pathways [12].
In addition to the wide variety of adverse effects, opioids use may also hamper 
the effects of the human body’s own natural pain killers, endorphins. Opioid 
administration reduces the production of beta-endorphins and impairs the func-
tion of mu-opioid receptors [13]. Beta-endorphins have significant natural analge-
sic effects and have been proposed to yield 18–33 times greater analgesic potency 
than morphine. Endorphin release is believed to enhance in response to a stressor, 
such as sharp pain, and can be quickly utilized to control the pain. The stressor 
causes the hypothalamus to release corticotrophin-releasing hormone (CRH), a 
peptide hormone and neurotransmitter, from the periventricular nucleus. CRH 
stimulates the cleavage of protein proopiomelanocortin (POMC) from basophilic 
cells, resulting in smaller proteins, one of them being beta-endorphin. In the 
peripheral nervous system, beta-endorphins bind to the μ receptors on both 
pre-synaptic and post-synaptic nerve terminals. The binding leads to the release 
of gamma-aminobutyric acid (GABA), which inhibits the release of substance P, a 
tachykinin protein involved in the transmission of pain. Endorphins not only have 
greater analgesic potency than morphine, but also enhances individuals’ mood 
and well-being, due to indirect elevation of dopamine [13]. In the central nervous 
system, beta-endorphins bind the μ receptors on the pre-synaptic nerve terminals 
and inhibit release of GABA, which normally inhibits the release of dopamine. The 
overall effect of beta-endorphins, which is decreased in opioid use, is a decrease in 
pain and an elevation in wellbeing.
6. The concept of opioid-free anesthesia
Opioid-free anesthesia is an anesthetic technique without intraoperative sys-
temic, neuraxial or intracavitary opioids, and that avoids perioperative opioids. 
There are a number of therapeutic uses and indications for opioid-free anesthesia 
including narcotic history (acute and chronic opioid addiction), opioid intolerance, 
morbidly obese patients with obstructive sleep apnea, hyperalgesia, history of 
chronic pain, immune deficiency, oncologic surgery, inflammatory disease, chronic 
obstructive pulmonary disease, and asthma [14].
Postoperative complications, such as respiratory depression, central muscle 
rigidity, pharyngeal muscle weakness, obstructed breathing, negative inotropism, 
nausea, vomiting, ileus and constipation, urinary retention, tolerance and addic-
tion, dizziness, and excessive somnolence, can be reduced or prevented. Decrease 
histamine release (allergy/anaphylaxis), increase patient satisfaction, and enhanced 
recovery after surgery and anesthesia (ERAS) are other beneficial effects of opioid-
free anesthesia [14–16].
Opioid-free anesthesia should be avoided in patients with allergy to any adju-
vant drugs, and should be used cautiously in patients with disorders of autonomic 
failure, cerebrovascular disease, critical coronary stenosis, acute coronary ischemia, 
heart block, extreme bradycardia, non-stabilized hypovolemic shock or polytrauma 
patients, controlled hypotension for minimal blood loss, and elderly patients on 
beta-blockers.
Interest and use of adjuvant modalities, including ketamine, gabapentinoids, 
intravenous lidocaine, magnesium sulfate, alpha-2 adrenoreceptor agonists, and 
beta-blockers, is increasing because of enhanced recovery, particularly in specific 
patient populations like chronic pain and opioid dependent patients [15].
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7. Opioid alternatives for postoperative pain control
In light of the serious adverse effects associated with opioids, many clini-
cians are forgoing prescribing opioids excessively and using opioid alternatives 
for postoperative pain control. These non-opioid alternatives, including acet-
aminophen, nonsteroidal anti-inflammatory drugs (NSAIDS)/cyclooxygenase-2 
(COX-2) inhibitors, gabapentin, local anesthetic infusion pumps, paravertebral 
or transverse abdominis plane nerve blocks, long-acting local anesthetics, and 
botulinum toxins, have been shown to produce analgesic effects and decrease 
opioid use postoperatively. Combinations of non-opioid alternatives have been 
shown to be superior in the management of postoperative pain and opioid 
requirements. In 2008, Parsa demonstrated that gabapentin and celecoxib in 
combination preoperatively for subpectoral breast augmentation was signifi-
cantly superior than celecoxib alone in reducing postoperative pain and opioid 
use [17]. Stephan and Parsa have extensive experience using non-opioid modali-
ties of postoperative pain control, which has resulted in significant reduction in 
opioid administration postoperatively for patients undergoing various plastic 
surgery procedures [13].
Several other opioid reduction strategies in a surgical setting have been 
tested and shown to be effective in managing pain and decreasing opioid use. 
Preoperative patient education has shown to be effective in reducing the opioid 
requirement postoperatively. Sugai et al. demonstrated that preoperative oral 
and written education concerning the body’s response to pain reduced preop-
erative and postoperative opioid prescriptions [18]. When comparing patients 
that had opioid-free procedures to the patients receiving adjunct opioids, Parsa 
et al. found statistically significant reduction in time from end of operation to 
discharge, unplanned postoperative hospital admissions, and opioid use in the 
post-anesthesia care unit [19].
8. Conclusions
Pain treatment and management has come a long way since ancient cultures. 
Several innovations during the nineteenth century made significant headway in 
opioid analgesics, and by the end of the twentieth century, hemodynamic stability 
during anesthesia was achievable through the application of opioids. However, in 
an era with significant opioid abuse, limiting opioid requirements in postopera-
tive pain management is of greater importance. Opioids are associated with 
unwanted side effects, including nausea, vomiting, dizziness, constipation, and 
hyperalgesia. Not only are there several adverse effects with opioid use, including 
a high addictive potential, opioids also interfere with beta-endorphins, the human 
body’s potent natural analgesic. Opioid-free anesthesia provides a technique that 
can achieve intraoperative hemodynamic stability, immobility, and postoperative 
analgesia without opioids, and therefore, in the absence of the significant associ-
ated side effects. Judicious utilization of adjuvants like ketamine, gabapentinoids, 
intravenous lidocaine, magnesium sulfate, alpha-2 adrenoreceptor agonists, and 
beta-blockers contribute to enhanced recovery in specific patients with chronic pain 
and opioid dependence. Opioid-free anesthesia and other opioid-free pain relief 
strategies are essential in the control of the opioid crisis, are key in effective analge-
sia without unwanted opioid-related side effects, and are needed for postoperative 
recovery.
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